Search

Your search keyword '"Levy-Barda A"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Levy-Barda A" Remove constraint Author: "Levy-Barda A" Database Unpaywall Remove constraint Database: Unpaywall
46 results on '"Levy-Barda A"'

Search Results

1. Supplemental Figure 4 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

2. Data from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

3. Supplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

4. Supplemental Figure 2 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

5. Supplemental Figure 1 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

6. Supplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

7. Supplementary Methods from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

8. Supplemental Figure 3 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

9. Supplemental Figure 5 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

10. Data from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

11. Supplemental Figure 1 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

12. Supplemental Figure 4 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

13. Supplemental Figure 3 from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

14. Supplementary Methods from Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

15. Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects

16. Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy

18. Discordant effects of ex-vivo JAK inhibition on inflammatory responses in colonic compared to ileal mucosa

19. Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy

20. 1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer

22. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

23. Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy

24. Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity

25. Abstract 2159: A pretreatment blood-based proteomic biomarker for enhanced decision-making in non-small cell lung cancer

26. Human intestinal epithelial cells can internalize luminal fungi via LC3-associated phagocytosis

27. Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity

28. Human intestinal epithelial cells can internalize luminal fungi via LC3-associated phagocytosis

29. A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profiling

30. Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study

31. Personalized approach for response prediction and treatment management for non-small cell lung cancer patients based on a liquid biopsy.

32. Mo1586: A MICROBIOTA TARGETED, MEDITERRANEAN DIET-BASED NUTRITIONAL EDUCATION PROGRAM POSITIVELY MODIFIES THE INTESTINAL ECOSYSTEM OF HEALTHY INDIVIDUALS

33. 24: HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZE LUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS

34. Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES

35. Detection of gene mutations and gene–gene fusions in circulating cell‐free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis

36. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

37. P313 Within, 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses

38. Durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: Three-month follow-up

39. Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα

40. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

42. PATH-24. DETECTION OF POINT MUTATIONS AND GENE FUSIONS FROM CIRCULATING CELL-FREE DNA (CFDNA) OF GLIOBLASTOMA (GBM) PATIENTS

44. The Ubiquitin E3/E4 Ligase UBE4A Adjusts Protein Ubiquitylation and Accumulation at Sites of DNA Damage, Facilitating Double-Strand Break Repair

45. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer

46. Involvement of the nuclear proteasome activator PA28γ in the cellular response to DNA double-strand breaks

Catalog

Books, media, physical & digital resources